亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

武漢楷倫公司銷售部  

埃索美拉唑,埃索美拉唑鎂三水合物,5-甲氧基-2-巰基-1H-苯并咪唑,頭孢雷特,普格拉雷等

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:童瑤
  • 電話:027-88395717
  • 郵件:kailun002@126.com
  • 傳真:027-88735683
  • QQ:2524490512
站內搜索
 
榮譽資質
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 62211-93-2卡培他濱的中間體的廠家
62211-93-2卡培他濱的中間體的廠家
單價 111.00 / kg對比
銷量 暫無
發貨 湖北武漢市付款后3天內
庫存 1kg起訂11kg
品牌 62211-93-2
型號 62211-93-2
規格 62211-93-2
過期 長期有效
更新 2013-09-26 11:11
 
詳細信息

產品名稱:1,2,3-三乙酰氧基-5-脫氧-D-核糖
62211-93-2卡培他濱的中間體的廠家
英文品名:1,2,3-triacetyl-5-deoxy-β-D-Riboturanose
CAS號:62211-93-2
別名:1,2,3-三乙酰-5-脫氧-D-核糖;1,2,3-三-O-乙酰基-5-脫氧-β-D-核糖;1,2,3-O-三乙酰基-5-脫氧-β-D-核糖;5-脫氧三乙酰核糖
分子式:C11H16O7
分子量:260.24
質量標準:企業內控標準
含量:98%
外觀性狀:白色結晶粉末
規格:醫藥中間體,62211-93-2是卡培他濱的中間體(Intermediate of Capecitabine)
©2025 武漢楷倫公司銷售部 版權所有   技術支持:化工網   訪問量:10685  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |